However, compared to GLP-1 receptor agonists and their confirmed cardiovascular protection, and benefits in patients with T2DM, the possible benefits of GIP receptor agonism are questionable because of its impaired effects on insulin secretion and lower potency of weight loss [58]. The gene discussed is INS; the disease is type 2 diabetes mellitus.